http___free-money-making-reviews.com_stand-up-to-cancer-awards-73-6-million-for-novel-groundbreaking-cancer-research-start-making-money-online-today_.xml
http___free-money-making-reviews.com_hr_stand-up-to-cancer-awards-73-6-million-for-novel-groundbreaking-cancer-research-start-making-money-online-today__1.xml
1.1 1.2 1.3 1.4 2.1 2.2 2.3 2.4 2.5 3.1 4.1 4.2 4.3 4.4 5.1 6.1 8.1 10.1 11.1 13.1 15.1 17.1 17.2 17.3 18.1 18.2 18.3 18.4 19.1 19.2 19.3 19.4 20.1 21.1 21.2 21.3 22.1 23.1 24.1 26.1 26.2 26.3 26.4 27.1 28.1 28.2 28.3 28.4 28.5 29.1 29.2 30.1 30.2 30.3 31.1 32.1 32.2 33.1 33.2 33.3 34.1 35.1 35.2 35.3 36.1 37.1 37.2 37.3 38.1 38.2 39.1 39.2 40.1 41.1 41.2 41.3 41.4 41.5 42.1 43.1 43.2 43.3 43.4 43.5 44.1 45.1 45.2 46.1 47.1 48.1 49.1 50.1 51.1 53.1 54.1 55.1 56.1 57.1 58.1 59.1 60.1 61.1 62.1 63.1 64.1 65.1 66.1 67.1 68.1 69.1 70.1 71.1 72.1 73.1 74.1 75.1 76.1 77.1 78.1 79.1 80.1 81.1
May 27, 2009, New York, NY / Los Angeles, CA: Stand Up To Cancer (SU2C), the Entertainment Industry Foundation’s charitable initiative supporting groundbreaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, has reached a significant milestone, awarding the first round of three-year grants â that total $73.6 million — to five multi-disciplinary, multi-institutional research Dream Teams. The majority of these funds were raised in connection with an SU2C telecast on September 5, 2008 that aired simultaneously on the ABC, CBS and NBC networks. Todayâs announcement comes on the one-year anniversary of the launch of Stand Up To Cancer. SU2Câs next round of funding â Innovative Research Grants for individual investigators â will be announced later this year. âRecent advancements in basic science and in technologies have placed us on the cusp of important discoveries that can revolutionize the fight against cancer,â said Nobel Laureate Phillip A. Sharp, Ph.D., Institute Professor at the Massachusetts Institute of Technology and David H. Koch Institute at MIT. Sharp chairs the Scientific Advisory Committee (SAC) assembled by SU2Câs scientific partner, the American Association for Cancer Research (AACR), that reviewed Dream Team applications and made recommendations on funding to SU2Câs Management Committee. âSU2C aims to capitalize on that progress and is pushing it forward at what will be an extraordinarily quick pace. The Dream Teams bring together leading laboratory scientists and physicians, collaborating in ways that are unprecedented with a laser-like focus on research that has enormous potential to help patients and save lives. The Stand Up To Cancer model could very well change the face of cancer.â Five SU2C Dream Team Grants Each Dream Teamâs project, funded for three years pending satisfactory achievement of stated milestones, is âtranslationalâ in nature, geared toward moving science from âbench to bedsideâ where it can benefit patients as quickly as possible. SU2Câs distinctive funding model was specifically designed to eliminate barriers that can inhibit creativity and collaboration, in part, by enabling scientists with different expertise from different institutions across the country â and in some cases, internationally â to work together. The five Dream Teams are comprised of 7 leaders, 4 co-leaders and 27 principal researchers from over 20 leading institutions, with more than 300 individuals participating in total. Each team will have at least two members from patient advocacy groups to ensure that the perspective of the patients and survivors they represent will be integrated into the research on an ongoing basis. The teams are listed below in alphabetical order according to the name of the leaders, and they will pursue the following important topics (full list of team members ATTACHED): âBringing Epigenetic Therapy to the Forefront of Cancer Managementâ/ Leader: Stephen B. Baylin, M.D., Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Co-Leader: Peter A. Jones, Ph.D., Distinguished Professor of Urology and Biochemistry & Molecular Biology, University of Southern California; âTargeting the PI3K Pathway in Womenâs Cancersâ/ Leader: Lewis C. Cantley, Ph.D., Chief of the Division of Signal Transduction at Beth Israel Deaconess Medical Center; Co-Leaders: Charles L. Sawyers, M.D., Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, and Gordon B. Mills, M.D., Ph.D., Chair, Department of Systems Biology, University of Texas M. D. Anderson Cancer Center; âAn Integrated Approach to Targeting Molecular Breast Cancer Molecular Subtypes and Their âResistanceâ Phenotypes â /Leaders: Joe W. Gray, Ph.D., Life Sciences Division Director, Lawrence Berkeley National Laboratory, and Dennis J. Slamon, M.D., Ph.D., Director of Clinical/Translational Research at UCLAâs Jonsson Comprehensive Cancer Center; âBioengineering and Clinical Applications of Circulating Tumor Cells Chipâ/ Leader: Daniel A. Haber, M.D., Ph.D., Director of the Massachusetts General Hospital Cancer Center; Co-Leader: Mehmet Toner, Ph.D., Professor of Biomedical Engineering, Harvard Medical School; and âCutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancerâ/ Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer Center at the University of Pennsylvania, and Daniel D. Von Hoff, M.D., Senior Investigator and Physician in Chief at the Translational Research Genomics Institute (TGen). The projects address some of the most critical and promising areas of cancer research today. They will enable scientists to gain new understanding of the molecular pathways and genetic mutations that contribute to the causes of many cancers; to apply nanotechnology to isolate and analyze circulating tumor cells; to explore imaging approaches that could lead to âstarvingâ tumors; to leverage the growing understanding of epigenetics to design targeted anticancer agents; and to explore new approaches to treating breast cancers, especially those resistant to current therapies. This unique translational research model focuses on the disease, drug targets and clinical development, combining research and clinical applications that have extraordinary potential for patients. âFor people struggling with this disease, or many of the 1.4 million Americans who will be diagnosed this year, scientific breakthroughs can literally be a matter of life or death,â said Laura Ziskin, executive producer of the September 5th, 2008 broadcast, who is a cancer survivor and a member of the SU2C Executive Leadership Council (ELC). âEvery single minute of every single day, we lose someone to cancer in this country. We urgently need more and better treatments, and we need everyone to support the scientists who are working so hard to develop more effective treatments. That, in a nutshell, is what Stand Up To Cancer is trying to facilitate.â Collectively, the research that will be done through the Dream Team projects could impact the diagnosis and treatment of a wide range of cancers in adults and children across ethnicities including, but not limited to pancreatic, breast, ovarian, cervical, uterine, brain, lung, prostate, rectal and colon, which represent two thirds of all U.S. cancer deaths. (562,340 people are expected to die of cancer in the United States this year.) In the U.S. alone, one out of three women and one out of two men will be diagnosed with cancer in their lifetimes. Worldwide, cancer kills almost eight million people annually. The combined award of $73.6 million fulfills one of Stand Up To Cancerâs key objectives: to assure that these translational research Dream Teams receive sufficient funding to see results within the three-year term of the grants. On behalf of Stand Up To Cancer, the American Association for Cancer Research (AACR) will be responsible for administering the grants, including distributing the funds to the Dream Team leadersâ institutions, developing methods of reporting and providing scientific oversight through program management and evaluation of progress during the funding period. AACR and the Scientific Advisory Committee will conduct periodic reviews to ensure that milestones and objectives are being satisfactorily achieved. Stand Up To Cancer is committed to ensuring that the funding process, as well as the outcomes of the projects, are transparent and that progress reports are made available to the public at www.su2c.org and www.aacr.org âThe response of the scientific community to Stand Up To Cancer has been extraordinary,â said Margaret Foti, Ph.D., M.D. (h.c.), CEO of AACR. âIt has been truly amazing to watch this bold new funding model, which was introduced just one year ago, grow into an unprecedented opportunity to move research forward for the benefit of cancer patients. The dedication and time commitment of our highly expert SU2C Scientific Advisory Committee have been quite remarkable and far beyond what is normally expected in a more standard research grant review process. Each and every one of AACRâs 28,000 members is very proud to be a part of this significant and exhilarating undertaking in cancer research, which will help us accelerate our mission of curing cancer at the earliest possible time.â Dream Teams Selected Through Rigorous and Transparent Process The Dream Team selection process began in July 2008 when AACR issued a call for research ideas. In response, Stand Up To Cancer received 237 submissions, representing thousands of researchers. All submissions were reviewed by the 20-member Scientific Advisory Committee (SAC), which includes highly accomplished basic scientists, physicians and patient advocates, chaired by Nobel Laureate Dr. Phillip A. Sharp and co-chaired by Drs. Arnold J. Levine and Brian J. Druker. The field was narrowed to 25 groups, then 16 and then eight. At that point, finalists were invited to submit full-blown research proposals. The leaders of each of the eight finalist teams met in-person with the SAC to present the plans for their research, and respond to questions about their projects â a level of interaction between applicants and reviewers that is unique in a scientific review process. The SAC made recommendations for the further development of proposals, where needed, and in two instances (in pancreatic cancer and breast cancer) where two teams proposed related approaches to research, the SAC suggested that the teams combine their proposals to create the strongest potential for producing optimal research results. The SACâs recommendations were reviewed and accepted by SU2Câs Management Committee, and were then approved by the Entertainment Industry Foundationâs (EIF) Board of Directors. Stand Up To Cancer is a program of EIF, a 501(c)(3) not-for-profit organization that serves as a collective charitable organization for the television and film businesses. [A full list of SAC members is attached.] SU2C As a Movement âStand Up To Cancer grew from two simple constructs: scientists need more money for research and easier ways to work together; and the entertainment industry has unique resources that can be called upon to help make every American aware that each and every one of us has a role to play in advancing cancer research,â said Sherry Lansing, EIF Board Chair and a member of the SU2C Executive Leadership Council (ELC). âFrom the person who can give five dollars to the philanthropist who can give millions, we are all connected to the devastation that cancer causes in our families, and together, we can Stand Up to end it.â Whether through providing in-kind services or mobilizing an array of organizations and individuals to build awareness and generate contributions, the entertainment industry is working to rally the public to Stand Up To Cancer. âToday is Stand UP To Cancerâs first birthday, and itâs thrilling to announce that all these incredible researchers are about to collaborate on five projects that have so much potential to reduce the suffering caused by this insidious disease,â said EIF CEO Lisa Paulsen, also a member of the SU2C ELC. âWe are enormously grateful to CBS, ABC and NBC for donating the time for last yearâs telecast, which was the catalyst that set all of this in motion, and to the 100 celebrities who volunteered their time to help get people involved.â Stand Up To Cancer Innovative Research Grants Fund Early Career Scientists TheSU2C Innovative Research Grantsare an effort to support the next generation of extraordinary leaders in their quest to conquer cancer. These grants will provide up to $750,000 over a three-year term, and will be awarded to early-career scientists whose novel, high-risk, high-reward research proposals have significant potential for translational application, but are often not funded by conventional sources. 415 grant applications have been received, and it is anticipated that in this first round of Innovative Research Grants, 10 to 12 will be awarded later this year. Stand Up To Cancer Garners Broad Support Major League Baseball was the first major donor to contribute to Stand Up To Cancer. âBaseball is an integral part of our countryâs heritage, and it has been a privilege for Major League Baseball to join the Stand Up To Cancer community to help fight a disease that has in some way affected virtually every family in our country,â said Baseball Commissioner Allan H. (Bud) Selig. âWe encourage our fans to get involved, to Stand Up and to become part of this groundbreaking effort to stop cancer.â Sidney Kimmel, the country’s largest individual supporter of cancer research, who pledged $25 million to SU2C during last year’s telecast, said, “SU2C’s intense, goal-directed, team-oriented approach is the next, most important step in the evolution of cancer research. If the Dream Teams produce tangible results over these next three years, the Stand Up To Cancer research model will be a paradigm shift on how cancer research is funded and conducted.” Other major SU2C supporters include Amgen, AARP, Bloomberg Philanthropies, GlaxoSmithKline, Revlon, Inter-American Development Bank (IDB), Wallis Annenberg & The Annenberg Foundation, Alliance for Global Good, New York Giants, Milken Family Foundation, Philips Electronics, Steve Tisch, The Island Def Jam Music Group and many others. In addition to ABC, CBS and NBC, SU2C major media partners include AOL, CondeÌ Nast Media Group, eBay Inc., Facebook, Hachette Filipacchi Media U.S., Hearst Corporation, Los Angeles Times, Meredith Corporation, The New York Times Company, Time Inc and WebMD. Individuals Participate in SU2C Through Online Community and Grassroots Activities SU2Câs robust online community, atwww.SU2C.org, offers various ways for people to share opinions and support, view video updates, contribute, and learn of ongoing initiatives and progress in the fight against cancer. The scope of donation opportunities on the SU2C website ranges from naming a star in honor of a loved one to web team challenges that encourage collaborative fundraising efforts by groups of various sizes all over the country. A novel Facebook application enables users to share their personal connections to cancer. The online community provides ample opportunity to share SU2Câs efforts via a variety of social media outlets, including Twitter, Facebook, AOL, MySpace, YouTube, flickr and several other sites that are accessible through the SU2C website. SU2C is implementing ongoing grassroots and community efforts, and is participating in national and regional events to raise awareness and funds. About the Stand Up To Cancer Initiative The Stand Up To Cancer (SU2C) movement raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the Fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against the disease. The SU2C Executive Leadership Council (ELC) includes Laura Ziskin, executive producer of the September 5thbroadcast, who is a cancer survivor; Sherry Lansing, who is the Chairperson of the Entertainment Industry Foundationâs Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; Katie Couric; Noreen Fraser, founder of the Noreen Fraser Foundation (NFF) and a cancer survivor; EIF Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; and nonprofit executive Ellen Ziffren. Representatives of 24 patient advocacy groups are members of SU2Câs Advocate Advisory Council. SU2C was formally launched on May 27, 2008. About the AACR The American Association for Cancer Research (AACR), which consists of over 28,000 scientists in the fight against cancer, is the oldest and largest scientific organization in the world focusing on every aspect of high-quality, innovative cancer research from the bench to the bedside. Lauded internationally for its scientific breadth, innovation and spread of new knowledge about cancer, the AACR is on the front lines in the quest for the prevention and cure of cancer. About the Entertainment Industry Foundation The Entertainment Industry Foundation (EIF), as a leading charitable organization of the entertainment industry, has distributed hundreds of millions of dollars to support programs addressing critical health, education and social issues. For additional information on Stand Up To Cancer, visit www.su2c.org Media Contacts: Thomas Chiodo tchiodo@rubenstein.com Jeremy Moore American Association for Cancer Research267-646-0557/ 609-519-0212 jeremy.moore@aacr.org MEDIA CONFERENCE CALLS TODAY, MAY 27th, 2009 Media Are Invited to Participate in Two Q&A Conference Calls Dial-in Information: U.S./Canada Dial-In #: 888.282.7404International Dial-In #: 763.488.9184 Call #1 from 12 PM to 1 PM EST/ (9 AM to 10 AM PST)Conference Code: 10324648 Participants: 10 Researchers from the newly announced Dream Teams Nobel Laureate Phillip A. Sharp, Ph.D.,Institute Professor at the Massachusetts Institute of Technology and David H. Koch Institute at MIT, Chair of SU2C Scientific Advisory Committee Raymond N. DuBois, M.D., Ph.D.,Provost and Executive Vice President, UT M.D. Anderson Cancer Center, SU2C Scientific Advisory Committee Margaret Foti, Ph.D., M.D. (h.c.), CEOof American Association for Cancer Research Lisa Paulsen, President and CEO, Entertainment Industry Foundation, SU2C Executive Leadership Committee Diane Balma, SU2C Executive Director Call #2 from 1:15 PM to 1:45 PM EST/ (10:15 AM to 10:45 AM PST)Conference Code: 10325316 Participants: Dana Delaney, Actress, SU2C Celebrity Ambassador Sherry Lansing, Former Studio Head, SU2C Executive Leadership Committee Laura Ziskin, Film Producer and Cancer Survivor, SU2C Executive Leadership Committee Lisa Paulsen, President and CEO, Entertainment Industry Foundation, SU2C Executive Leadership Committee William G. Nelson, V, M.D., Ph.D., Director and Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, SU2C Scientific Advisory Committee Raymond N. DuBois, M.D., Ph.D.,Provost and Executive Vice President, UT M.D. Anderson Cancer Center, SU2C Scientific Advisory Committee Margaret Foti, PhD., M.D. (h.c.), CEO, American Association for Cancer Research Diane Balma, SU2C Executive Director Return To SU2C Press Releases By Anonymous
1.1 1.2 1.3 1.4 2.1 2.2 2.3 2.4 2.5 2.6 3.1 4.1 4.2 4.3 4.4 5.1 6.1 6.2 6.3 8.1 8.2 8.3 8.4 10.1 11.1 11.2 11.3 13.1 13.2 15.1 15.2 15.3 17.1 17.2 17.3 18.1 18.2 18.3 19.1 19.2 19.3 20.1 21.1 21.2 21.3 22.1 24.1 26.1 26.2 26.3 27.1 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 28.10 29.1 29.2 30.1 30.2 30.3 31.1 32.1 33.1 34.1 35.1 35.2 36.1 37.1 37.2 38.1 38.2 39.1 39.2 40.1 41.1 41.2 41.3 41.4 41.5 42.1 43.1 43.2 43.3 43.4 43.5 44.1 45.1 45.2 46.1 47.1 48.1 49.1 50.1 51.1 53.1 54.1 55.1 56.1 57.1 58.1 59.1 60.1 62.1 63.1 64.1 64.2 64.3 65.1 65.2 66.1 67.1 68.1 69.1 70.1 71.1 72.1 73.1 74.1 75.1 76.1 76.2 77.1 77.2 78.1 79.1 80.1 81.1
27. svibnja 2009, New York, NY / Los Angeles, CA: Stand Up to Cancer (SU2C), industrija zabave Zaklade dobrotvorna inicijativa podupire revolucionarnu istraživanja u cilju dobivanja novih liječenja raka pacijentima u ubrzanom roku, dosegla značajnu prekretnicu , dodjeljuje prvi krug trogodišnjih potpora â € "da je ukupno 73,6 milijuna dolara - za pet multidisciplinarnih, multi-institucionalnih istraživačkih timova Dream. Većina tih sredstava su podignute u svezi s SU2C televizijska emisija na 5. rujna 2008 koji se emitirao istovremeno na ABC, CBS i NBC mreže. Todayâ € ™ s najava dolazi na jednogodišnju obljetnicu lansiranja Stand Up To Cancer. SU2Câ € ™ s idući krug financiranja â € "Inovativna istraživanja Potpore za pojedine istražiteljima â €" bit će objavljen kasnije ove godine. â € œRecent napredak u temeljne znanosti i tehnologije u nas stavljen na vrhuncu značajnih otkrića koja može revolucionirati borbu protiv raka, â € rekao je dobitnik Nobelove nagrade Phillip A. Sharp, dr.sc., Institut profesor na Massachusetts Institute of Technology i David H. Koch Institut na MIT-u. Oštri stolice Znanstveni savjetodavni odbor (SAC) okupio SU2Câ € ™ s znanstveno partner, Američka udruga za istraživanje raka (AACR), da komentiran Dream Team aplikacije i napravio preporuke o financiranju SU2Câ € ™ s Upravnog odbora. â € œSU2C želi kapitalizirati na tom napretku i to gura naprijed, na što će biti iznimno brz tempo. The Dream Timovi okupiti vodeće laboratorijske znanstvenike i liječnike, surađuju na načine koji su nevidjeni s laserski poput naglaskom na istraživanjima koja ima ogroman potencijal da pomogne pacijentima i spasiti živote. Stand Up To Cancer modela mogao vrlo dobro promijeniti lice cancer.â € Pet SU2C Dream Team Grantovi Svaki san Teamâ € ™ s projektima koje financira tri godine čeka zadovoljavajuće ostvarenje navedenih događaja, je â € œtranslationalâ € u prirodi, usmjerena prema kreće znanost od â € œbench da bedsideâ € gdje se može imati koristi bolesnika što je brže moguće. SU2Câ € ™ s prepoznatljivim modela financiranja posebno je dizajniran kako bi se uklonili barijere koje mogu spriječiti kreativnost i suradnju, u dijelu, omogućujući znanstvenicima s različitih stručnih znanja iz različitih institucija diljem zemlje â € "te u nekim slučajevima, međunarodno â €" da rade zajedno . Pet Dream Timovi su se sastojale od sedam lidera, 4 co-vođa i 27 glavnih istraživača iz više od 20 vodećih institucija, s više od 300 pojedinaca koji sudjeluju u ukupno. Svaka ekipa će imati najmanje dva člana iz pacijenata zagovaranja skupine kako bi se osiguralo da perspektiva pacijenata i preživjelima oni predstavljaju bit će integrirana u istraživanja na trajnoj osnovi. Timovi su navedene u nastavku abecednim redom prema imenu lidera, i oni će nastaviti sljedeće važne teme (puni popis članova tima u prilogu): â € œBringing epigenetske terapija na čelu raka Managementâ € / voditelj: Stephen B. Baylin, MD, zamjenik ravnatelja Sidney Kimmel Opsežan Cancer Center u Johns Hopkins, Co-Leader: Peter A. Jones, Ph.D., Uvaženi Profesor urologiju i biokemiju & molekularnu biologiju, Sveučilišta u Južnoj Kaliforniji; â € œTargeting na PI3K put u womenâ € ™ s Cancersâ € / Voditelj: Lewis C. Cantley, dr.sc., načelnik Odjela za prijenos signala na Bet Israel đakonica Medical Center; Co-Vođe: Charles L. Sawyers, MD , direktor Odjela za ljudska onkologiju i patogenezi program na Memorial Sloan-Kettering Cancer Center i Gordon B. Mills, MD, Ph.D., predsjednik, Odjel za biologiju, Sveučilište Systems of Texas MD Anderson Cancer Center; â € œAn Integrirani pristup ciljanja molekularnu raka dojke molekularnih podtipova i njihovih â € œResistanceâ € fenotipova â € / Vođe: Joe W. Gray, dr.sc., Life Sciences Division direktor, Lawrence Berkeley nacionalni laboratorij, i Dennis J. Slamon, MD, Ph.D., direktor Kliničkog / Translacijska istraživanja u UCLAâ € ™ s Jonsson Sveobuhvatna Cancer Center; â € œBioengineering i kliničke primjene cirkulirajućih stanica tumora Chipâ € / Voditelj: Daniel A. Haber, MD, Ph.D., direktor Massachusetts General Hospital Cancer Center, Co-Leader: Mehmet Toner, dr.sc., profesor Biomedical Engineering, Harvard Medical School, a â € œCutting isključili dovod goriva: Novi pristup liječenju gušterače Cancerâ € / Vođe: Craig B. Thompson, MD, direktor, Abramson Cancer Center na Sveučilištu u Pennsylvaniji, i Daniel D. Von Hoff, MD, viši istraživač i liječnik u načelnika na translacijska istraživanja Genomics Institute (TGen). Projekti rješavanje nekih od najkritičnijih i perspektivna područja istraživanja raka danas. Oni će omogućiti znanstvenicima da dobije novo razumijevanje molekularnih putova i genetske mutacije koje doprinose uzroka mnogih vrsta raka, primijeniti nanotehnologiju izolirati i analizirati cirkulirajućih stanica, kako bi se istražiti imaging pristupe koji bi mogli dovesti do € œstarvingâ € tumora; na utjecati na rastuću razumijevanje epigenetike dizajnirati ciljane antikancerogena agenti, te da istražuju nove pristupe liječenju raka dojke, posebno onih otpornih na tekuće terapije. Ova jedinstvena prijevodni istraživanje modela fokusira na bolesti, droga ciljeva i klinički razvoj, kombinirajući istraživanja i kliničke aplikacije koje imaju izniman potencijal za pacijente. â € œFor ljudi bore s tom bolešću, ili mnogi od 1,4 milijuna Amerikanaca koji će se ove godine dijagnosticiran, znanstvena otkrića doslovno može biti pitanje života ili smrti, â € rekao je Laura Ziskin, izvršni producent 5. rujna 2008 emitiranje , koji je preživio rak i član Izvršnog SU2C Leadership vijeća (ELC). â € œEvery ni minute svaki dan, izgubit ćemo nekoga s rakom u ovoj zemlji. Mi hitno trebamo više i bolje tretmane, i trebamo svi podržati znanstvenike koji rade tako teško razviti učinkovitije tretmane. To je, ukratko, je ono Stand Up To Cancer pokušava facilitate.â € Sveukupno, istraživanje koje će biti učinjeno kroz projekte Dream Team mogli utjecati na dijagnozu i liječenje širokog spektra tumora u odraslih i djece diljem nacionalnosti, uključujući, ali ne ograničavajući se gušterače, dojke, jajnika, grlića maternice,, mozak, pluća , prostate, rektuma i debelog crijeva, koji predstavljaju dvije trećine svih američkih smrtnih slučajeva raka. (562.340 ljudi očekuje se da će umrijeti od raka u SAD-u ove godine.) U SAD-u, jednoj od tri žene i jedan od dvojice muškaraca bit će dijagnosticiran rak u njihovim životima. Diljem svijeta, rak ubija gotovo osam milijuna ljudi godišnje. Kombinirani nagrada 73,6 milijuna dolara ispunjava jedan od Stand Up Za Cancerâ € ™ s ključnih ciljeva: kako bi se osiguralo da ove translacijska istraživanja Dream Timovi dobivaju dovoljno sredstava kako bi vidjeli rezultate u roku od tri godine od donacija. U ime Stand Up To Cancer, Američka udruga za istraživanje raka (AACR) će biti odgovoran za administriranje potpore, uključujući i raspodjelu sredstava za Dream Team leadersâ € ™ institucije, razvijaju metode izvješćivanja i pružanja znanstvene nadzor kroz upravljanje programom i evaluacija napretka tijekom razdoblja financiranja. AACR i Znanstveni savjetodavni odbor će provoditi periodične preglede kako bi se osiguralo da prekretnice i ciljevi su zadovoljavajući se postiže. Stand Up To Cancer je počinio kako bi se osiguralo da se sredstva proces, kao i rezultati projekata, koji su transparentni i da su izvješća o napretku dostupni javnosti www.su2c.org www.aacr.org â € œThe odgovor znanstvene zajednice na Stand Up to Cancer je izvanredna, â € rekao je Margaret Foti, dr.sc., MD (HC), predsjednik Uprave AACR. â € œIt je uistinu nevjerojatna gledati ovu podebljano novi modela financiranja, koji je uveden tek prije godinu dana, raste u bez mogućnosti da se presele istraživanja prema naprijed za dobrobit pacijenata oboljelih od raka. Predanost i vrijeme predanost naših visoko stručne SU2C Znanstvenog savjetodavnog odbora bili prilično neobičan i daleko izvan onoga što se obično očekuje u više standardnih istraživanja grant proces revizije. Svaki jedan od AACRâ € ™ s 28.000 članova je vrlo ponosan da bude dio ovog značajnog i uzbudljivo poduzetnika u istraživanju raka, koji će nam pomoći ubrzati našu misiju liječenju raka u najkraćem mogućem time.A € Dream timovi Odabrani kroz rigorozne i transparentnom procesu Izbor Dream Team proces je počeo u srpnju 2008, kada AACR izdao poziv za istraživačke ideje. U odgovoru, Stand Up To Cancer primio 237 podnesaka, što predstavlja tisuće istraživača. Svi podnesci su pregledani od strane 20-članog Znanstvenog savjetodavnog odbora (SAC), koja uključuje vrlo postigli osnovne znanstvenike, liječnike i strpljiv zagovara, pod predsjedanjem nobelovca Dr. Phillip A. Sharp i supredsjedaju DRS. Arnold J. Levine i Brian J. Druker. Polje je suzio na 25 skupine, zatim 16 i onda osam. U tom trenutku, finalisti su pozvani da dostave full-puhano istraživačke prijedloge. Čelnici svaku od osam finalista momčadi susreli su se u-osobe sa SAC predstaviti planove za istraživanja i odgovoriti na pitanja o svojim projektima â € "razina interakcije između zahtjeva i recenzenata koji je jedinstven u znanstvenom postupku pregleda . SAC dala preporuke za daljnji razvoj prijedloga, gdje je to potrebno, au dva slučaja (u raka gušterače i raka dojke), gdje dvije ekipe predložio povezane pristupe istraživanju, SAC je predložio da se timovi kombinirati svoje prijedloge kako bi stvorili najjači potencijal za proizvodnju optimalne rezultate istraživanja. Saca € ™ s preporuka je pregledao i prihvaćen od strane SU2Câ € ™ s Upravnog odbora, a zatim su odobreni od strane industrije zabave Foundationâ € ™ s (EIF) Upravni odbor. Stand Up To Cancer je program investicijskom fondu, 501 (c) (3) ne-za-dobit organizacija koja služi kao kolektivno dobrotvorne organizacije za televizijske i filmske tvrtke. [Puni popis članova SAC je u prilogu.] SU2C Kao pokreta â € œStand Up To Cancer rastao od dvije jednostavne konstrukata: znanstvenici potrebno više novca za istraživanje i lakši načini da rade zajedno, a industrija zabave ima jedinstvene resurse koji mogu biti pozvani pomoći kako bi svaki američki svjesni da svatko od nas ima ulogu u promicanju istraživanju raka, â € rekao je Sherry Lansing, EIF odbor predsjedavajući i član Izvršnog SU2C Leadership vijeća (ELC). â € œFrom osoba koja može dati pet dolara na filantrop koji može dati milijune, svi smo povezani na razaranja koja rak uzrokuje u našim obiteljima, a zajedno možemo izdržati do kraja it.â € Bilo kroz davanje u naturi usluge ili mobiliziranje niz organizacija i pojedinaca za izgradnju svijesti i generirati doprinosa, industrija zabave radi na rally javnost stajati do raka. â € œToday je stand up Cancerâ € ™ s prvi rođendan, i itâ € ™ s uzbudljivim objaviti da su sve ove nevjerojatne istraživači su oko surađivati na pet projekata koji imaju toliko potencijala da smanji patnje uzrokovane ovim podmukle bolesti, € rekao je izvršni direktor EIF Lisa Paulsen, također član SU2C ELC. â € œWe su enormno zahvalan CBS, ABC i NBC za doniranje vremena za zadnji yearâ € ™ s TV prijenos, koji je bio katalizator koji postavili sve to u pokretu, i do 100 slavne osobe koje su dobrovoljno svoje vrijeme kako bi se ljudi koji su uključeni . â € Stand Up To Cancer Research Grants inovacijskog fonda ranoj karijeri Znanstvenici U SU2C Inovativna istraživanja Potpore su napori kako bi podržao novu generaciju izvanrednih lidera u njihovoj potrazi za osvajanje rak. Ovi grantovi će osigurati do 750.000 dolara tijekom tri godine, te će se dodjeljivati za rano karijere znanstvenika čiji roman, visokog rizika, visokog nagrada prijedlozi istraživanja imaju značajan potencijal za prevodilačke primjenu, ali se često ne financira konvencionalnih izvora . 415 za dodjelu bespovratnih sredstava su primili, a predviđeno je da se u ovom prvom krugu inovativnog istraživanja donacija, 10-12 dodijelit će se kasnije ove godine. Stand Up to Cancer garners široku potporu Major League Baseball je prvi veliki donator doprinijeti Stand Up To Cancer. â € œBaseball je sastavni dio našeg countryâ € ™ s baštini, i to je bio privilegija za Major League Baseball pridružiti Stand Up to Cancer zajednice pomoći u borbi protiv bolesti koja je na neki način utjecati na gotovo svaka obitelj u našoj zemlji , â € rekao Bejzbol povjerenik Allan H. (Bud) Selig. â € œWe ohrabriti naše navijače da se uključe, ustati i postati dio tog revolucionarnog nastojanju da se zaustavi cancer.â € Sidney Kimmel, zemlje najveći pojedinačni pristaša istraživanje raka, koji je obećao 25 milijuna dolara kako bi SU2C tijekom prošlogodišnjeg TV prijenos, rekao je, "SU2C je intenzivna, cilj-usmjerena, timski orijentirani pristup je sljedeći, najvažniji korak u evoluciji istraživanje raka . Ako Dream timovi proizvesti opipljive rezultate tijekom ove naredne tri godine, Stand Up to Cancer istraživačkog modela će biti paradigme o tome kako istraživanje raka financira i provodi. Ostale glavne SU2C navijači su Amgen, AARP, Bloomberg Philanthropies, GlaxoSmithKline, Revlon, Inter-American Development Bank (IDB), Wallis Annenberg & The Annenberg Foundation, Savez za Global Dobar, New York Giantsa, Milken Family Foundation, Philips Electronics, Steve Tisch , Island Def Jam Music Group i mnogi drugi. Osim ABC, CBS i NBC, SU2C glavni medijski partneri su AOL, CondeÌ Nast Media Group, eBay Inc, Facebook, Hachette Filipacchi Media SAD, Hearst Corporation, Los Angeles Times, Meredith Corporation, New York Times Company, vrijeme Inc i WebMD. Pojedinci Sudjelovati u SU2C Kroz online zajednice i grassroots Aktivnosti SU2Câ € ™ s robustan online zajednica, atwww.SU2C.org, nudi različite načine za ljude da dijele mišljenja i podršku, pregled video ažuriranja, doprinose, i naučiti o tijeku inicijative i napretka u borbi protiv raka. Opseg donacije mogućnosti na SU2C web varira od imenovanja zvijezda u čast voljene na web team izazovima koji potiču suradnju prikupljanje sredstava napore po skupinama razne veličine diljem zemlje. Zahtjev roman Facebook omogućuje korisnicima da podijele svoje osobne veze s rakom. Online zajednica pruža dovoljno prilika za razmjenu SU2Câ € ™ s naporima putem raznih društvenih medija, uključujući Twitter, Facebook, AOL, MySpace, YouTube, Flickr i nekoliko drugih mjesta koji su dostupni putem web stranice SU2C. SU2C provodi u tijeku Grassroots i zajednice naporima, te sudjeluje u nacionalnoj i regionalnoj događaja za podizanje svijesti i sredstava. O Stand Up To Cancer inicijative Stand Up to Cancer (SU2C) pokret prikuplja financijska sredstva za ubrzati tempo revolucionarnog translacijska istraživanja koje se mogu dobiti nove terapije za pacijente brzo i spasiti živote. U jesen 2007, skupina žena čiji su životi su sve bili pogođeni raka u dubokim načina počeo raditi zajedno kako bi se rasporediti resurse medija i zabavne industrije u borbi protiv bolesti. SU2C Izvršni Vodstvo vijeće (ELC) uključuje Laura Ziskin, izvršni producent rujna 5thbroadcast, koji je preživio rak; Sherry Lansing, koji je predsjednik industriji zabave Foundationâ € ™ s Upravni odbor i osnivač Sherry Lansing Zaklade ; EIF predsjednik i izvršni direktor Lisa Paulsen, Katie Couric, Noreen Fraser, osnivač Noreen Fraser Foundation (NFF) i raka preživjelog; EIF potpredsjednik Kathleen Lobb; Rusty Robertson i Sue Schwartz je Robertson Schwartz Agencije, i neprofitna izvršne Ellen Ziffren . Predstavnici 24 skupina bolesnika zagovaranja su članovi SU2Câ € ™ s nezavisnog Savjetodavnog vijeća. SU2C službeno je pokrenuta na 27. svibnja 2008. O AACR Američka udruga za istraživanje raka (AACR), koji se sastoji od više od 28.000 znanstvenika u borbi protiv raka, je najstarija i najveća znanstvena organizacija u svijetu s naglaskom na svakom aspektu visoke kvalitete, inovativnog istraživanja raka s klupe u krevet . Hvaljen inozemstvo za svoje znanstvene širinu, inovacije i širenje novih znanja o raku, AACR je na prvim linijama u potrazi za prevenciju i liječenje raka. O Zaklade industriji zabave Šoubiznis zaklada (EIF), kao jedan od vodećih dobrotvorne organizacije industriji zabave, distribuira stotine milijuna dolara za potporu programima rješavaju kritične zdravstvo, obrazovanje i socijalna pitanja. Za dodatne informacije o Stand Up To Cancer, posjetite www.su2c.org Mediji Kontakti: Thomas Chiodo tchiodo@rubenstein.com Jeremy Moore Američko udruženje za rak Research267-646-0557 / 609-519-0212 jeremy.moore @ aacr.org MEDIJI konferencijske pozive DANAS, 27. svibnja 2009 Mediji su pozvani da sudjeluju u dva Q & Conference Pozivi Dial-u informacijama: SAD / Kanada Dial-U #: 888.282.7404International Dial-u #: 763.488.9184 Sudionici: Istraživači iz nedavno najavljenih Dream timova Nobelovac Phillip A. Sharp, dr.sc., Institut profesor na Massachusetts Institute of Technology i David H. Koch Institut na MIT-u, predsjedavajući SU2C Znanstvenog savjetodavnog odbora Raymond N. DuBois, MD, Ph.D., Provost i izvršni dopredsjednik, UT MD Anderson Cancer Center, SU2C Znanstveni savjetodavni odbor Margaret Foti, Dr.sc., MD (HC), izvršni direktor Američkog udruženja za istraživanje raka Lisa Paulsen, predsjednik i glavni izvršni direktor, Šoubiznis zaklada, SU2C Izvršni odbor Vodstvo Diane Balma, SU2C izvršni direktor Poziv # 2 13:15 do 13:45 EST / (10:15-10:45 PST) Konferencija Šifra: 10325316 Sudionici: Dana Delaney, glumica, SU2C Celebrity veleposlanik Sherry Lansing, bivši šef Studio, SU2C Izvršni odbor Vodstvo Laura Ziskin, filmski producent i raka preživjelog, SU2C Izvršni odbor Vodstvo Lisa Paulsen, predsjednik i glavni izvršni direktor, Šoubiznis zaklada, SU2C Izvršni odbor Vodstvo William G. Nelson, V, MD, Ph.D., direktor i profesor, Sidney Kimmel Sveobuhvatna Cancer Center, Sveučilišta Johns Hopkins, SU2C Znanstveni savjetodavni odbor Raymond N. DuBois, MD, Ph.D., Provost i izvršni dopredsjednik, UT MD Anderson Cancer Center, SU2C Znanstveni savjetodavni odbor Margaret Foti, dr. sc., MD (HC), izvršni direktor, Američka udruga za istraživanje raka Diane Balma, SU2C izvršni direktor Povratak na SU2C Priopćenja Do Anoniman